Commerzbank Aktiengesellschaft FI trimmed its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 5.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 371,370 shares of the biopharmaceutical company’s stock after selling 21,983 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Pfizer were worth $9,411,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of the stock. Bessemer Group Inc. boosted its holdings in Pfizer by 11.1% in the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock valued at $3,358,000 after acquiring an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK raised its position in shares of Pfizer by 1.2% during the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock worth $35,817,000 after purchasing an additional 17,032 shares during the period. CHURCHILL MANAGEMENT Corp acquired a new stake in shares of Pfizer during the first quarter worth about $8,283,000. Alta Advisers Ltd raised its position in shares of Pfizer by 69.6% during the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company’s stock worth $809,000 after purchasing an additional 13,100 shares during the period. Finally, WCM Investment Management LLC raised its position in Pfizer by 8.7% in the 1st quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company’s stock valued at $3,176,000 after buying an additional 10,051 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.
Pfizer Trading Down 0.1%
Shares of PFE stock opened at $24.59 on Thursday. The stock has a market capitalization of $139.79 billion, a PE ratio of 17.82, a P/E/G ratio of 0.90 and a beta of 0.58. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The business has a 50-day moving average of $23.99 and a 200 day moving average of $24.77. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96.
Pfizer Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.00%. The ex-dividend date is Friday, July 25th. Pfizer’s payout ratio is presently 124.64%.
Analyst Ratings Changes
PFE has been the subject of a number of analyst reports. Wolfe Research raised their price target on Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a research note on Wednesday, April 30th. The Goldman Sachs Group raised their price target on Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. UBS Group raised their price target on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Jefferies Financial Group raised their price target on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, May 21st. Finally, Berenberg Bank decreased their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Thursday, May 29th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $28.55.
View Our Latest Stock Report on Pfizer
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
- Five stocks we like better than Pfizer
- Best Stocks Under $5.00
- Cameco’s 80% 3-Month Gain May Be Just the Start
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 3 Stocks to Benefit From Lower Rates Before 2025 Ends
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Citigroup Earnings Could Signal What’s Next for Markets
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.